FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RIGGS STEVEN				2. Issuer Name and		0,	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) 951 CALLE AMANECER			3. Date of Earliest 02/24/2017	Transaction (M	onth/Day/Year)	X Officer (give title Other (spec below) below) VP Operations							
951 CALLE AMANECER (Street) SAN CLEMENTE CA 92673 (City) (State) (Zip)				4. If Amendment, E	ate of Original	Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Grou Form filed by One Form filed by Mor Person	e Reporting Per	son			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3) 2. Transaction			2. Transaction	2A. Deemed	3.	4. Securities Acquired (A) or		5. Amount of	6. Ownership	7. Nature			

2. Transaction Date (Month/Day/Year)	Execution Date, if any	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned	Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
		Code	v	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	(1150.4)	(Instr. 4)
02/24/2017		X		16,250	Α	\$58.79	17,576	D	
02/24/2017		S ⁽¹⁾		4,500	D	\$ 151.3881 ⁽²⁾	13,076	D	
02/24/2017		S ⁽¹⁾		11,750	D	\$ 152.2282 ⁽³⁾	1,326	D	
02/24/2017		X		15,000	Α	\$58.79	16,326	D	
02/24/2017		S ⁽¹⁾		4,796	D	\$ 151.4907 ⁽⁴⁾	11,530	D	
02/24/2017		S ⁽¹⁾		10,204	D	\$152.2044 ⁽⁵⁾	1,326	D	
	Date (Month/Day/Year) 02/24/2017 02/24/2017 02/24/2017 02/24/2017 02/24/2017 02/24/2017 02/24/2017	Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) 02/24/2017 02/24/2017 02/24/2017 02/24/2017 02/24/2017 02/24/2017 02/24/2017 02/24/2017 02/24/2017 02/24/2017	Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transac Code (Ir 8) 02/24/2017 X 02/24/2017 S ⁽¹⁾	Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) 02/24/2017 X V 02/24/2017 S ⁽¹⁾ S ⁽¹⁾ 02/24/2017 S ⁽¹⁾ X 02/24/2017 X S ⁽¹⁾ 02/24/2017 X S ⁽¹⁾ 02/24/2017 X S ⁽¹⁾ 02/24/2017 X S ⁽¹⁾	Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) Disposed O 02/24/2017 K K 4,500 02/24/2017 S ⁽¹⁾ 4,500 02/24/2017 S ⁽¹⁾ 11,750 02/24/2017 S ⁽¹⁾ 11,750 02/24/2017 S ⁽¹⁾ 4,796	Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) Disposed OF (D) (Instr. 8) 02/24/2017 Code V Amount (A) or (D) 02/24/2017 X I 16,250 A 02/24/2017 S ⁽¹⁾ I 4,500 D 02/24/2017 S ⁽¹⁾ I 11,750 D 02/24/2017 X I 15,000 A 02/24/2017 S ⁽¹⁾ I 4,796 D	Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) Disposed Of (D) (Instr. 3, 4 and 5) 02/24/2017 Code V Amount (A) or (D) Price 02/24/2017 X I 16,250 A \$58.79 02/24/2017 S ⁽¹⁾ I 4,500 D \$151.3881 ⁽²⁾ 02/24/2017 S ⁽¹⁾ I 11,750 D \$152.2282 ⁽³⁾ 02/24/2017 X I 15,000 A \$58.79 02/24/2017 S ⁽¹⁾ I 41,750 D \$152.2282 ⁽³⁾ 02/24/2017 S ⁽¹⁾ I 4,796 D \$151.4907 ⁽⁴⁾	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(
			3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$ 58.79	02/24/2017		x			16,250	(6)	02/24/2024	Common Stock	16,250	\$58.79 ⁽⁷⁾	46,250	D	
Non- Qualified Stock Option (right to buy)	\$58.79	02/24/2017		x			15,000	(6)	02/24/2024	Common Stock	15,000	\$58.79 ⁽⁷⁾	31,250	D	

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on August 11, 2016.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$150.95 to \$151.90, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$151.95 to \$152.85, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$150.95 to \$151.90, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$151.95 to \$152.80, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

6. Twenty-five percent of the shares shall vest on each of the first, second, third, and fourth anniversaries of the grant date . Fifty percent of the vested shares shall become exercisable if, during the term of the option, the closing price of the Company's common stock is equal to or more than one-hundred and twenty-five percent of the exercise price per share for thirty consecutive trading days. The remaining fifty percent of the vested shares shall become exercisable if, after the date of award and on or before the expiration date, the closing price of the Company's common stock is equal to or more than one-hundred and fifty percent of eh exercise price for 30 consecutive trading days.

7. Transaction is the exercise of a derivative security; see Column 2.

By: Paula Darbyshire,

C. Riggs

02/27/2017 Attorney-in-fact For: Steven

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.